Anhedonia is a core feature of depressive disorders. The galanin N-terminal fragment (1-15) plays a role in mood regulation since it induces depression and anxiogenic-like effects in rats. In this study, we analysed galanin N-terminal fragment (1-15) actions in anhedonic-like behaviours in rats using operant and non-operant tests and the areas involved with these effects.
Methods:
Galanin N-terminal fragment (1-15) effects were analysed in saccharin self-administration, sucrose preference, novelty-suppressed feeding and female urine sniffing tests. The areas involved in galanin N-terminal fragment (1-15)-mediated effects were studied with positron emission tomography for in vivo imaging, and we analysed the ventral tegmental area and nucleus accumbens. Galanin N-terminal fragment (1-15) had effects on the mRNA expression of the dopamine transporters Dat and Vmat2; the C-Fos gene; the dopamine receptors D1, D2, D3, D5; and the galanin receptors 1 and 2.
Results:
Galanin N-terminal fragment (1-15) at a concentration of 3 nmol induced a strong anhedonia-like phenotype in all tests. The involvement of galanin receptor 2 was demonstrated with the galanin receptor 2 antagonist M871 (3 nmol). The 18F-fluorodeoxyglucose positron emission tomography images indicated the action of galanin N-terminal fragment (1-15) over several nuclei of the limbic system. Galanin N-terminal fragment (1-15)-mediated effects also involved changes in the expression of Dat, Vmat2, D3 and galanin receptors in the ventral tegmental area as well as the expression of C-Fos, D1, D2 and D3 and TH immunoreactivity in the nucleus accumbens.
Conclusions:
Our results indicated that galanin N-terminal fragment (1-15) exerts strong anhedonic-like effects and that this effect was accompanied by changes in the dopaminergic mesolimbic system. These results may provide a basis for the development of novel therapeutic strategies using galanin N-terminal fragment (1-15) analogues for the treatment of depression and reward-related diseases.
AlbertPRLe FrancoisBMillarAM (2011) Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Mol Brain4: 21.
2.
AlenFSantosAMoreno-SanzGet al. (2009) Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors. Neuroscience158: 465–473.
3.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, (5th ed. DSM-V). Washington, DC: American Psychiatric Association.
4.
BardeSRueggJPrud’hommeJet al. (2016) Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proc Natl Acad Sci U S A113: E8472–E8481.
BartfaiTLuXBadie-MahdaviHet al. (2004) Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A101: 10470–10475.
7.
BellidoIDiaz-CabialeZJimenez-VasquezPAet al. (2002) Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci Lett317: 101–105.
8.
Borroto-EscuelaDONarvaezMDi PalmaMet al. (2014) Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex. Biochem Biophys Res Commun452: 347–353.
BressanRACrippaJA (2005) The role of dopamine in reward and pleasure behaviour–review of data from preclinical research. Acta Psychiatr Scand111(Suppl 427): 14–21.
11.
CadoniCPisanuASimolaNet al. (2017) Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence. Neuropharmacology123: 385–394.
12.
DedicNWalserSMJanMet al. (2011) Mouse models of depression. In: UeharaDT (ed.) Psychiatric Disorders-Trends and Developments. In Tech, pp. 185–222.
13.
Der-AvakianAMarkouA (2012) The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci35: 68–77.
14.
DiazJPilonCLe FollBet al. (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci20: 8677–8684.
15.
Diaz-CabialeZParradoCFuxeKet al. (2007) Receptor-receptor interactions in central cardiovascular regulation. Focus on neuropeptide/alpha(2)-adrenoreceptor interactions in the nucleus tractus solitarius. J Neural Transm114: 115–125.
16.
Diaz-CabialeZParradoCNarvaezMet al. (2010) Neurochemical modulation of central cardiovascular control: The integrative role of galanin. EXS102: 113–131.
17.
Diaz-CabialeZParradoCVelaCet al. (2005) Role of galanin and galanin(1-15) on central cardiovascular control. Neuropeptides39: 185–190.
18.
EidelbergD. (2009) Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci32: 548–557.
19.
EttenbergA (2009) The runway model of drug self-administration. Pharmacol Biochem Behav91: 271–277.
20.
Ferres-CoyAGalofreMPilar-CuellarFet al. (2016) Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration. Mol Psychiatry21: 328–338.
21.
Flores-BurgessAMillonCGagoBet al. (2017) Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression. Neuropharmacology118: 233–241.
22.
Flores-BurgessAMillónCGagoBet al. (2018) Small interference RNA knockdown rats in behavioral functions: GALR1/GALR2 heteroreceptor in anxiety and depression-like behavior. In: KFaDOBorroto-Escuela (ed.) Receptor-Receptor Interactions in the Central Nervous System. New York: Humana Press, pp. 133–148.
23.
FuxeKBorroto-EscuelaDORomero-FernandezWet al. (2012) On the existence and function of galanin receptor heteromers in the central nervous system. Front Endocrinol (Lausanne)3: 127.
24.
FuxeKMarcellinoDRiveraAet al. (2008) Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev58: 415–452.
25.
Garcia-PerezDNunezCLaordenMLet al. (2016) Regulation of dopaminergic markers expression in response to acute and chronic morphine and to morphine withdrawal. Addict Biol21: 374–386.
26.
GendersSGSchellerKJDjoumaE (2018) Neuropeptide modulation of addiction: Focus on galanin. Neurosci Biobehav Rev. Epub ahead of print 24 June 2018. DOI: 10.1016/j.neubiorev.2018.06.021.
27.
GoldMSBlumKFeboMet al. (2018) Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front Biosci (Schol Ed)10: 309–325.
28.
GorwoodP (2008) Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci10: 291–299.
29.
HedlundPBFuxeK (1996) Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Ann N Y Acad Sci780: 193–212.
30.
HedlundPBYanaiharaNFuxeK (1992) Evidence for specific N-terminal galanin fragment binding sites in the rat brain. Eur J Pharmacol224: 203–205.
31.
JacobowitzDMKresseASkofitschG (2004) Galanin in the brain: Chemoarchitectonics and brain cartography–a historical review. Peptides25: 433-464.
32.
JuhaszGHullamGEszlariNet al. (2014) Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci U S A111: E1666–E1673.
33.
KormosVGasznerB (2013) Role of neuropeptides in anxiety, stress, and depression: From animals to humans. Neuropeptides47: 401–419.
34.
KuteevaEHokfeltTOgrenSO (2005) Behavioural characterisation of transgenic mice overexpressing galanin under the PDGF-B promoter. Neuropeptides39: 299–304.
35.
KuteevaEHokfeltTWardiTet al. (2008a) Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci65: 1854–1863.
36.
KuteevaEWardiTHokfeltTet al. (2007) Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur Neuropsychopharmacol17: 64–69.
37.
KuteevaEWardiTLundstromLet al. (2008b) Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology33: 2573–2585.
38.
LeggioGMSalomoneSBucoloCet al. (2013) Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol719: 25–33.
39.
LuXBarrAMKinneyJWet al. (2005) A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci U S A102: 874–879.
40.
MalkesmanOAustinDRTragonTet al. (2012) Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol15: 1135–1148.
41.
MalkesmanOScattoniMLParedesDet al. (2010) The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry67: 864–871.
42.
ManningCEWilliamsESRobisonAJ (2017) Reward network immediate early gene expression in mood disorders. Front Behav Neurosci11: 77.
43.
MarcoEMBallestaJAIralaCet al. (2017) Sex-dependent influence of chronic mild stress (CMS) on voluntary alcohol consumption; study of neurobiological consequences. Pharmacol Biochem Behav152: 68–80.
44.
MarquezPVSaxenaS (2016) Making mental health a global priority. Cerebrum2016: cer-10-16.
45.
MillonCFlores-BurgessACastilla-OrtegaEet al. (2019) Central administration of galanin N-terminal fragment 1-15 decreases the voluntary alcohol intake in rats. Addict Biol24: 76–87.
46.
MillonCFlores-BurgessANarvaezMet al. (2017) The neuropeptides Galanin and Galanin(1-15) in depression-like behaviours. Neuropeptides64: 39–45.
47.
MillonCFlores-BurgessANarvaezMet al. (2016) Galanin (1-15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: Involvement of the raphe-hippocampal 5-HT neuron system. Brain Struct Funct221: 4491–4504.
48.
MillonCFlores-BurgessANarvaezMet al. (2015) A role for galanin N-terminal fragment (1-15) in anxiety- and depression-related behaviors in rats. Int J Neuropsychopharmacol18: 1–13.
49.
MitsukawaKLuXBartfaiT (2008) Galanin, galanin receptors and drug targets. Cell Mol Life Sci65: 1796–1805.
50.
NestlerEJCarlezonWAJr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry59: 1151–1159.
51.
Pascual-BrazoJCastroEDiazAet al. (2012) Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int J Neuropsychopharmacol15: 631–643.
52.
PaxinosGWatsonC (2007) The Rat Brain in Stereotaxic Coordinates, Sixth Edition. London: Academic Press.
53.
PrietoECollantesMDelgadoMet al. (2011) Statistical parametric maps of (1)(8)F-FDG PET and 3-D autoradiography in the rat brain: A cross-validation study. Eur J Nucl Med Mol Imaging38: 2228–2237.
54.
RussoSJNestlerEJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci14: 609–625.
55.
Sanchis-SeguraCSpanagelR (2006) Behavioural assessment of drug reinforcement and addictive features in rodents: An overview. Addict Biol11(1): 2-38.
56.
SwansonCJBlackburnTPZhangXet al. (2005) Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A102: 17489–17494.
57.
TatemotoKRokaeusAJornvallHet al. (1983) Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett164: 124–128.
58.
WeissJMBonsallRWDemetrikopoulosMKet al. (1998) Galanin: A significant role in depression?Ann N Y Acad Sci863: 364–382.
59.
WillnerP (2005) Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology52: 90–110.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
